Shilpa Medicare's Unit IV receives Eurasia GMP approval
Drug Approval

Shilpa Medicare's Unit IV receives Eurasia GMP approval

Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia

  • By IPP Bureau | December 28, 2024

Shilpa Medicare Limited, Unit IV, Jadcherla, Telangana, India and Shilpa Medicare Ltd, Unit VII, Nacharam, Hyderabad, Telangana, India had undergone a GMP inspection by Ministry of Health, Belarus for GMP certification from the Eurasian Economic Union in October 2024.

Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia, the member countries for which are Belarus, Russia, Kazakhstan, Kyrgyzstan, and Armenia.

This approval will open up significant business opportunities in these countries. Unit IV of Shilpa Medicare Lid. is engaged in the manufacture, testing, release and distribution of sterile Injectable and non-sterile Oral finished dosage forms in the US, Europe and rest of the world markets. Unit VII of Shilpa Medicare Ltd. is engaged in testing raw materials, packing materials, finished dosage forms and other testing activities.

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International